ArticleEndocrinology2026
IL-22 increases proglucagon-expressing enteroendocrine cells via STAT3 in human iPSC-derived intestinal epithelium.
Article in Endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Intestinal epithelial differentiation is tightly regulated to maintain tissue homeostasis and systemic metabolic function. Although the intrinsic transcriptional programs governing enteroendocrine cell (EEC) development have been characterized extensively, the role of extrinsic immune signals in directing lineage specification is not completely understood. In particular, how cytokine signaling influences differentiation of EEC subtypes remains unclear. Here, we investigated the role of interleukin-22 (IL-22) in EEC differentiation using human induced pluripotent stem cell-derived intestinal organoids and in vivo models. IL-22 selectively increased proglucagon (GCG) expression and the number of glucagon-like peptide-1 (GLP-1)-positive EECs without affecting other EEC markers. This effect was associated with enhanced expression of the lineage-related transcription factors neurogenin 3 and forkhead box A2. Pharmacological inhibition of signal transducer and activator of transcription 3 (STAT3) signaling attenuated the IL-22-induced increases in GCG expression and GLP-1-positive cell abundance, indicating a role of STAT3 in mediating these effects. Mechanistically, relatively high expression of IL-22 receptor subunit alpha 1 in undifferentiated epithelial cells was associated with STAT3 activation induced by IL-22. Consistent with these findings, in vivo IL-22 administration increased intestinal GCG expression and GLP-1 levels in the circulation and intestinal tissue. Importantly, our findings indicate that IL-22 does not globally promote EEC differentiation but rather selectively directs epithelial lineage commitment toward the GCG-positive EEC fate. These results suggest that IL-22/STAT3 signaling induces human intestinal epithelial differentiation into GCG-positive EECs and may represent a strategy for modulating epithelial cell fate to influence systemic metabolic homeostasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.